Hemoptysis

Disclaimer: This information is intended for educational purposes and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional, considering the individual patient's circumstances, current medical evidence, and local guidelines. This content does not replace the need for professional clinical judgment.

Overview

• Definition: Hemoptysis is the expectoration of blood from the respiratory tract. It signifies bleeding from the airways or lung parenchyma. It must be differentiated from pseudohemoptysis (bleeding from the nasopharynx or oropharynx) and hematemesis (vomiting of blood from the gastrointestinal tract).
  • Pseudohemoptysis: Blood from nosebleeds (epistaxis) or oral/pharyngeal lesions (e.g., gingival bleeding, tonsillitis).
  • Hematemesis: Vomited blood, often dark, "coffee-ground" appearance, mixed with food particles, acidic pH. May be preceded by nausea or abdominal discomfort.
  • Hemoptysis: Coughing up blood, usually bright red, frothy, mixed with sputum, alkaline pH. May be associated with dyspnea or chest discomfort.
• Epidemiology: The incidence varies widely based on geographic region and prevalence of underlying diseases. Globally, tuberculosis and bronchiectasis remain common causes. In developed countries, acute and chronic bronchitis, bronchiectasis, and lung cancer are leading causes.
  • Prevalence: Common symptom, estimated to occur in up to 10% of pulmonary clinic visits.
  • Mortality: Directly related to the volume of blood loss and the underlying cause. Massive hemoptysis has a high mortality rate (up to 50-100% if untreated) primarily due to asphyxiation rather than hypovolemia.
• Classification: Hemoptysis is primarily classified by the volume of blood expectorated over a specific time frame, as this dictates urgency of management.
  • Trace Hemoptysis: Blood-streaked sputum.
  • Mild Hemoptysis: Less than 20 mL/24 hours (e.g., a few teaspoons).
  • Moderate Hemoptysis: 20 mL to 200 mL/24 hours (e.g., a few tablespoons to half a cup).
  • Severe (Massive) Hemoptysis: Defined as expectoration of ≥100 mL to 200 mL of blood in 24 hours, or ≥50 mL/hour, or any volume that causes hemodynamic instability or respiratory compromise, or requires intubation. This definition varies slightly between sources (e.g., some define it as >600 mL in 24-48 hours, or 150 mL in one hour). The practical definition emphasizes immediate threat to life due to airway obstruction.

Pathophysiology

• Mechanism: The lungs receive a dual blood supply:
  • Bronchial Arteries (90% of bleeds): Originate from the aorta (systemic circulation), supply the tracheobronchial tree, pleura, and hilar lymph nodes. They are under high pressure and flow. Bleeding from bronchial arteries is the most common cause of significant hemoptysis.
  • Pulmonary Arteries (5% of bleeds): Originate from the right ventricle (pulmonary circulation), supply the alveoli. They are under low pressure and high flow. Bleeding from pulmonary arteries often indicates severe parenchymal disease (e.g., cavitating lesions, pulmonary vasculitis, AV malformations).
  • Other Sources (5%): Non-bronchial systemic arteries (e.g., intercostal, internal mammary arteries), or diffuse alveolar hemorrhage.
  • Bleeding typically occurs when underlying pathology disrupts the integrity of the vascular structures within the bronchial tree or lung parenchyma, allowing blood to enter the airways. The cough reflex expels the blood.
• Risk Factors:
  • Infections: Bronchitis (acute/chronic), bronchiectasis, tuberculosis (active or prior), aspergilloma, lung abscess, pneumonia (especially necrotizing).
  • Malignancy: Bronchogenic carcinoma (squamous cell carcinoma particularly), metastatic cancer to the lung.
  • Cardiovascular: Mitral stenosis (pulmonary hypertension, bronchial vein rupture), pulmonary embolism with infarction, AV malformations, congestive heart failure.
  • Autoimmune/Vasculitis: Granulomatosis with polyangiitis (Wegener's), Goodpasture syndrome, systemic lupus erythematosus, microscopic polyangiitis.
  • Trauma: Blunt or penetrating chest trauma, iatrogenic (e.g., post-biopsy, central line placement).
  • Iatrogenic: Anticoagulation (therapeutic or supratherapeutic), thrombolytic therapy, bronchoscopy with biopsy.
  • Others: Cryptogenic hemoptysis (no identifiable cause), foreign body aspiration, cystic fibrosis, endometriosis (catamenial hemoptysis).
• Protective Factors: Not directly applicable to preventing hemoptysis itself, but maintaining overall lung health and treating underlying conditions can reduce risk.
  • Smoking Cessation: Reduces risk of chronic bronchitis, COPD, and lung cancer.
  • Vaccinations: Against influenza and pneumococcus can prevent respiratory infections.
  • Early Treatment of Lung Infections: Prevents progression to destructive lung disease (e.g., bronchiectasis, cavitary lesions).
  • Good Control of Chronic Diseases: Such as diabetes, which can predispose to infections.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Coughing up blood (bright red, frothy, mixed with sputum).
  • Sensation of warmth or bubbling in the chest prior to hemoptysis.
  • Dyspnea (especially with significant bleeding).
  • Chest discomfort or tightness.
• Early Signs:
  • Blood-streaked sputum (mildest form).
  • Recurrent, small volume hemoptysis.
  • New or worsening cough.
  • Weight loss, fatigue, night sweats (suggestive of chronic disease like TB or malignancy).
• Advanced Signs:
  • Massive hemoptysis (rapidly increasing volume, choking, gasping).
  • Signs of respiratory distress: tachypnea, accessory muscle use, cyanosis.
  • Hypotension, tachycardia (signs of hypovolemic shock, less common unless bleeding is truly massive and sustained).
  • Altered mental status due to hypoxemia.
• Atypical Presentations:
  • Hemoptysis occurring only with menstruation (catamenial hemoptysis, suggesting thoracic endometriosis).
  • Hemoptysis following dental procedures or epistaxis (pseudohemoptysis).
  • Vomiting blood (hematemesis) initially mistaken for hemoptysis.

Physical Examination

• Inspection:
  • General appearance: Distress, respiratory rate, use of accessory muscles, cyanosis, pallor.
  • Oropharynx: Check for blood from nasal passages, gums, or oral lesions.
  • Neck veins: Elevated JVP may suggest right heart strain or pulmonary hypertension.
  • Chest wall: Scars, deformities, signs of trauma.
• Palpation:
  • Tracheal deviation: May indicate tension pneumothorax or large mediastinal mass.
  • Lymphadenopathy: Cervical or supraclavicular nodes may suggest malignancy or infection.
  • Tactile fremitus: May be increased over areas of consolidation/collapse.
• Percussion:
  • Dullness: Over areas of consolidation, pleural effusion, or atelectasis.
• Auscultation:
  • Crackles (rales): Indicate fluid in alveoli (blood, exudate, transudate). Can be localized to the bleeding site.
  • Rhonchi: Suggest secretions in large airways.
  • Wheezing: Localized wheeze may indicate partial airway obstruction (tumor, foreign body, blood clot). Diffuse wheezing may indicate reactive airway disease.
  • Diminished or absent breath sounds: Suggests pneumothorax, large pleural effusion, or complete bronchial obstruction.
  • Cardiac auscultation: Murmurs (e.g., mitral stenosis), rubs.
• Special Tests: Not typically part of physical exam for hemoptysis but may be indicated:
  • Pulse oximetry: To assess oxygen saturation.
  • Point-of-care ultrasound (POCUS): Can rapidly assess for pleural effusion, pneumothorax, or consolidated lung.

Diagnostic Approach

History Taking

• Key Questions:
  • Volume: How much blood? (teaspoons, cups, continuous soakage). Quantify over 24 hours. "How many times have you filled a cup/bowl?"
  • Duration: How long has this been happening? Acute or chronic?
  • Character of blood: Bright red, dark, frothy, clotted, mixed with sputum?
  • Associated symptoms: Fever, chills, night sweats, weight loss (infection, malignancy)? Dyspnea, chest pain (PE, cardiac, pneumonia)? Sinusitis, rash, arthralgias (vasculitis)? Abdominal pain, nausea, vomiting (GI source)?
  • Past medical history: Lung disease (TB, bronchiectasis, COPD, CF), cardiac disease, autoimmune disorders, malignancy, bleeding disorders.
  • Medications: Anticoagulants (warfarin, DOACs), antiplatelets (aspirin, clopidogrel), NSAIDs.
  • Smoking history: Pack-years.
  • Environmental exposures: Silica, asbestos.
  • Travel history: Endemic areas for TB or fungal infections.
  • Prior hemoptysis episodes: Frequency, severity, diagnosed cause.
• Red Flags:
  • Massive hemoptysis (any volume causing respiratory distress or hemodynamic instability).
  • Recurrent hemoptysis.
  • Age > 40 years with significant smoking history (increased cancer risk).
  • Systemic symptoms (unexplained weight loss, fevers, night sweats).
  • Unexplained anemia.
  • History of malignancy.
  • Signs of respiratory distress or hemodynamic compromise on presentation.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): Assess hemoglobin/hematocrit (for blood loss), white blood cell count (infection), platelet count (coagulopathy).
  • Coagulation Profile (PT/INR, aPTT): Assess for coagulopathy, especially if on anticoagulants or liver disease is suspected.
  • Blood Type and Crossmatch: Essential for massive hemoptysis for potential transfusion.
  • Renal Function (BUN, Creatinine): To assess kidney function, especially in vasculitis syndromes (e.g., Goodpasture, GPA) or if contrast is needed for imaging.
  • Electrolytes: To assess overall metabolic status.
  • Arterial Blood Gas (ABG): To assess gas exchange and acid-base status in patients with respiratory distress.
• Confirmatory (based on clinical suspicion):
  • Sputum Analysis:
    • Gram stain and culture (bacterial infection).
    • Acid-fast bacilli (AFB) stain and culture (tuberculosis).
    • Fungal stains and cultures (aspergilloma, other fungal infections).
    • Cytology (malignancy, though sensitivity is low).
  • Autoimmune Serologies: Antineutrophil cytoplasmic antibodies (ANCA: PR3-ANCA, MPO-ANCA) for GPA, MPA; anti-glomerular basement membrane (GBM) antibodies for Goodpasture syndrome; ANA, anti-dsDNA for SLE.
  • Cardiac Markers: If acute coronary syndrome or pulmonary embolism is suspected.
  • D-dimer: If pulmonary embolism is suspected (low probability, to rule out).
• Monitoring:
  • Serial CBCs: To monitor for ongoing blood loss and response to treatment.
  • Serial coagulation profiles: If coagulopathy is being managed.

Imaging

• Recommended:
  • Chest X-ray (CXR): Initial imaging for all patients. Can identify infiltrates, masses, cavities, hilar enlargement, pleural effusions, or cardiac enlargement. However, CXR is often normal or non-specific in hemoptysis, and a normal CXR does not rule out significant pathology.
  • High-Resolution Computed Tomography (HRCT) of the Chest with IV Contrast: This is the gold standard for localizing the source of bleeding and identifying underlying lung pathology. Crucial for guiding therapy (e.g., bronchial artery embolization). It can identify bronchiectasis, cavitary lesions, tumors, pulmonary arteriovenous malformations (PAVMs), or active bleeding. CT angiography (CTA) protocol is often preferred to delineate vascular anatomy.
• Advanced:
  • Bronchial Artery Angiography: Diagnostic and therapeutic. Performed by interventional radiologists, it directly visualizes bronchial and non-bronchial systemic arteries and is the definitive step before bronchial artery embolization.
  • Pulmonary Angiography: If a pulmonary arterial source (e.g., AV malformation, PE) is suspected and not clearly seen on CT.
  • Virtual Bronchoscopy (CT-based): Can aid in planning for flexible or rigid bronchoscopy.
  • V/Q Scan or CTA Pulmonary Angiogram: If pulmonary embolism is suspected.

Management

Acute Management (Especially for Massive Hemoptysis)

The immediate priorities are airway protection, ventilation, oxygenation, and control of bleeding. - Immediate (within minutes): * Airway Protection: Most critical step. * Positioning: Place the patient in a lateral decubitus position with the bleeding lung dependent (down) to prevent blood from spilling into the contralateral (unaffected) lung, if the source is known. If the source is unknown, position supine or slightly Trendelenburg. * Suction: Aggressive suctioning of the airway is essential. * Intubation: If respiratory compromise or inability to clear secretions, intubate with a large-bore endotracheal tube (ETT) (≥ 8.0 mm ID) to allow for bronchoscopy and suction. A double-lumen ETT or a single-lumen ETT with a bronchial blocker can be used to selectively ventilate the non-bleeding lung. - Stabilization (within first hour): * Oxygenation: High-flow oxygen (non-rebreather mask or heated high-flow nasal cannula). * Hemodynamic Support: * Large-bore IV access (at least two peripheral IVs). * Fluid resuscitation (crystalloids, blood products) for hypovolemia. * Transfusion of packed red blood cells, fresh frozen plasma, platelets as needed based on CBC, coagulation studies, and active bleeding. * Reverse Coagulopathy: If present (e.g., Vitamin K, FFP, prothrombin complex concentrate for warfarin; specific reversal agents for DOACs). * Consultations: Early consultation with interventional pulmonology, interventional radiology, thoracic surgery, and anesthesia. - Emergency (Bleeding Control): * Bronchoscopy (Rigid or Flexible): * Diagnostic: To localize the bleeding site (identifies ~90% of sources), guide interventions, and remove clots. * Therapeutic: * Topical vasoconstrictors: Instillation of cold saline, epinephrine (1:20,000 to 1:100,000), or tranexamic acid through the bronchoscope. * Balloon tamponade: Inflation of a Fogarty balloon catheter or specific bronchial blocker beyond the bleeding site to occlude the bronchus. * Electrocautery/Laser coagulation: For focal lesions. * Bronchial Artery Embolization (BAE): The treatment of choice for massive hemoptysis due to bronchial artery bleeding. Performed by interventional radiologists, it involves selectively cannulating and embolizing the bleeding bronchial artery with coils, Gelfoam, or particles. High success rate (~80-90%) in immediate control. * Surgical Resection (Lobectomy/Pneumonectomy): Reserved for patients who fail BAE, have persistent life-threatening bleeding, have an anatomically resectable lesion (e.g., aspergilloma, tumor, localized bronchiectasis), or have a major vessel rupture. High mortality in unstable patients.

Chronic Management (for non-massive or resolved hemoptysis)

• Pharmacological:
  • Tranexamic Acid (TXA): An antifibrinolytic agent.
    • Oral: For mild-moderate hemoptysis or recurrent hemoptysis. Dose: 500-1000 mg orally every 8 hours.
    • Intravenous: For more significant, non-massive bleeding or as adjunct. Dose: 10 mg/kg IV every 8 hours.
    • Nebulized: Emerging use for mild-moderate hemoptysis. Dose: 500-1000 mg in 5-10 mL saline, nebulized 2-3 times daily.
  • Antibiotics: For active infections (e.g., acute bronchitis, pneumonia, lung abscess, exacerbation of bronchiectasis). Specific antibiotics chosen based on suspected pathogen and local resistance patterns.
  • Antituberculosis drugs: If TB is diagnosed.
  • Antifungals: For aspergilloma or other fungal infections (e.g., voriconazole, itraconazole).
  • Immunosuppressants: For autoimmune or vasculitic causes (e.g., corticosteroids, cyclophosphamide, rituximab).
  • Bronchodilators/Corticosteroids: For COPD/asthma exacerbations contributing to hemoptysis.
• Non-pharmacological:
  • Smoking Cessation: Crucial for chronic bronchitis, COPD, and lung cancer.
  • Airway Clearance Techniques: For bronchiectasis (e.g., chest physiotherapy, flutter valve).
  • Pulmonary Rehabilitation: For chronic lung diseases.
  • Hydration: To loosen secretions.
  • Nutritional support: Important for patients with chronic lung disease or malignancy.
• Monitoring:
  • Follow-up Imaging: Repeat CXR or CT chest to assess resolution of underlying pathology or identify new lesions.
  • Sputum studies: For persistent infection.
  • Clinical Surveillance: For recurrence of hemoptysis or worsening of underlying disease.

Treatment Algorithms

• First-Line (Massive Hemoptysis):
  1. ABC Stabilization: Airway protection (intubation, selective lung isolation), ventilation, oxygenation. Place bleeding lung dependent.
  2. Hemodynamic support: IV fluids, blood products. Reverse coagulopathy.
  3. Localization and Intervention:
     • Emergent Bronchoscopy: Localize source, clear clots, temporary tamponade.
     • Bronchial Artery Embolization (BAE): Often the definitive first-line intervention for bronchial artery source.
• Second-Line (Massive Hemoptysis):
  1. Repeat BAE: If initial embolization fails or bleeding recurs.
  2. Surgical Resection: If BAE fails, bleeding is life-threatening and resectable, or a major vessel rupture.
  3. Other embolization: Consider non-bronchial systemic arteries or pulmonary artery embolization if source identified.
• First-Line (Non-Massive Hemoptysis):
  1. Diagnostic Workup: Thorough history, labs, HRCT chest.
  2. Treat Underlying Cause:
     • Antibiotics for infection.
     • Antituberculosis drugs for TB.
     • Antifungals for aspergilloma.
     • Management of cardiac conditions (e.g., mitral stenosis).
     • Consider TXA (oral or nebulized).
• Refractory Cases:
  • Persistent non-massive hemoptysis: May require repeat diagnostic workup, consideration of more invasive procedures (e.g., bronchoscopy with laser, argon plasma coagulation) if a focal lesion is identified, or repeat BAE if the initial one was unsuccessful or recurrence from the same source.
  • Chronic recurrent hemoptysis: Long-term management of underlying disease. In some cases of severe, debilitating bronchiectasis not amenable to BAE, surgical resection may be considered.

Complications

• Common:
  • Anxiety and psychological distress.
  • Anemia (with chronic or recurrent bleeding).
  • Atelectasis (due to blood clots obstructing airways).
• Serious:
  • Asphyxiation: The leading cause of death in massive hemoptysis, due to blood filling the airways and impairing gas exchange.
  • Hypovolemic shock: Less common than asphyxiation, but can occur with extremely rapid and massive blood loss.
  • Acute Respiratory Failure: Due to aspiration of blood into the contralateral lung.
  • Pneumonia: Aspiration pneumonia from blood.
  • Re-bleeding: Common after initial control, especially with BAE (recurrence rates up to 10-20% at 1 year).
  • Complications of procedures:
    • BAE: Spinal cord ischemia (paraplegia, rare but devastating), stroke, pseudoaneurysm, dissection, renal injury from contrast.
    • Surgery: Bleeding, infection, broncho-pleural fistula, ARDS.
• Long-term:
  • Chronic lung damage if underlying cause not addressed (e.g., worsening bronchiectasis, pulmonary fibrosis).
  • Psychological impact from living with a potentially life-threatening condition.
  • Risk of recurrence.

Prognosis

• Factors Affecting Outcome:
  • Volume of hemoptysis: Massive hemoptysis carries the highest mortality.
  • Underlying cause: Malignancy and destructive lung diseases (e.g., multi-drug resistant TB, severe bronchiectasis) generally have poorer prognoses. Cryptogenic hemoptysis has a good prognosis.
  • Patient comorbidities: Older age, poor lung function, cardiac disease, and immunosuppression worsen outcomes.
  • Timeliness and effectiveness of intervention: Prompt and effective management of massive hemoptysis significantly improves survival.
• Survival:
  • Overall mortality from hemoptysis varies greatly depending on the cause and severity.
  • Massive hemoptysis mortality can be 50-100% without intervention, reduced to 10-20% with aggressive management (BAE, surgery).
  • Mortality from non-massive hemoptysis is low, primarily related to the underlying disease.
• Quality of Life: Chronic or recurrent hemoptysis can significantly impair quality of life due to anxiety, fear of re-bleeding, and symptoms of underlying lung disease. Successful treatment of the underlying cause or definitive intervention for bleeding can improve QoL.

Prevention

• Primary: Preventing initial occurrence of conditions that cause hemoptysis.
  • Smoking cessation: Prevents chronic bronchitis, COPD, and lung cancer.
  • Vaccination: Against influenza and pneumococcus to reduce respiratory infections.
  • Infection control: Proper hygiene to prevent spread of respiratory infections.
  • Tuberculosis control: Screening and treatment of latent TB infection in high-risk individuals.
• Secondary: Early detection and intervention to prevent progression or recurrence.
  • Prompt diagnosis and treatment of lung infections: To prevent chronic lung damage (e.g., bronchiectasis).
  • Regular follow-up: For patients with chronic lung diseases to manage exacerbations.
  • Optimizing anticoagulation: Careful monitoring of INR/aPTT in patients on warfarin/heparin to prevent supratherapeutic levels.
• Tertiary: Preventing complications and improving functional outcomes after an episode.
  • Long-term management of underlying disease: To prevent recurrence (e.g., adherence to TB treatment, control of bronchiectasis).
  • Pulmonary rehabilitation: To improve lung function in patients with chronic lung disease.
  • Patient education: On warning signs of re-bleeding and when to seek urgent medical attention.

Special Populations

• Pediatric:
  • Causes: Foreign body aspiration, cystic fibrosis, congenital heart disease (e.g., Eisenmenger syndrome), congenital airway anomalies, infections (pertussis, adenovirus), trauma. TB is also a concern in endemic areas.
  • Management: Airway management can be more challenging due to smaller airways. BAE is effective but technically more challenging due to smaller vessel size.
• Geriatric:
  • Causes: Increased prevalence of lung cancer, COPD, bronchiectasis, and cardiovascular disease. More likely to be on anticoagulants.
  • Management: Higher risk of complications from invasive procedures. Co-morbidities often limit therapeutic options. Careful assessment of functional status and goals of care.
• Pregnancy:
  • Causes: Exacerbation of pre-existing lung conditions (e.g., bronchiectasis), pulmonary embolism (increased risk in pregnancy), peripartum cardiomyopathy.
  • Management: Diagnostic imaging may require shielding or reduced radiation dose (e.g., V/Q scan over CTA if PE is suspected). Certain medications (e.g., some antifungals, immunosuppressants) may be contraindicated. BAE is generally safe but requires careful monitoring of the fetus.
• Comorbidities:
  • Immunocompromised: Higher risk of opportunistic infections (e.g., fungal, NTM), leading to cavitary lung disease and hemoptysis. Management involves treating the underlying infection and optimizing immune status.
  • Renal Failure: Increased risk of uremic coagulopathy. Vasculitis syndromes can involve both lung and kidney (e.g., Goodpasture's, GPA).
  • Cardiovascular Disease: Consider mitral stenosis, pulmonary embolism, heart failure as causes. Anticoagulation may need to be adjusted or reversed.

Clinical Pearls

• Diagnostic:
  • Always exclude pseudohemoptysis and hematemesis first. Ask about symptoms like nausea/vomiting, recent nosebleeds, gum bleeding.
  • HRCT chest with IV contrast is paramount. A normal CXR should never exclude the need for CT, especially with significant hemoptysis, recurrent episodes, or risk factors for malignancy.
  • Bronchoscopy for localization (if source unknown/unclear on CT) and therapeutic intervention. For massive hemoptysis, it's diagnostic and therapeutic.
  • Consider the "unholy trinity" for massive hemoptysis: bronchiectasis, tuberculosis, and aspergilloma.
  • Think systemic diseases: Vasculitis, connective tissue diseases can present with hemoptysis and multi-organ involvement.
• Treatment:
  • Protect the unaffected lung first. This is the priority over stopping the bleed in massive hemoptysis, as asphyxiation is the main cause of death.
  • Bronchial artery embolization is the intervention of choice for most massive hemoptysis. It is less invasive than surgery and highly effective.
  • Tranexamic acid (TXA) can be very useful for mild-moderate hemoptysis or as an adjunct, especially nebulized.
  • Surgical resection is a definitive treatment but carries higher risks. Reserve for specific indications (failed BAE, resectable tumor, localized disease).
• Pitfalls:
  • Underestimating the severity of hemoptysis. Even seemingly small volumes can indicate a critical underlying condition or herald massive bleeding.
  • Delay in obtaining advanced imaging (CT) or specialist consultation. Time is critical in massive hemoptysis.
  • Failing to differentiate hemoptysis from other sources of bleeding.
  • Treating only the bleeding and not the underlying cause.
  • Ignoring risk factors for malignancy, especially in smokers over 40.

Recent Updates

• Guidelines: Recent guidelines emphasize early and aggressive airway management for massive hemoptysis, with BAE as the preferred initial treatment for bronchial artery bleeding. Increasing recognition of nebulized tranexamic acid for non-massive hemoptysis.
• Evidence: Growing evidence supports the safety and efficacy of BAE, with ongoing refinement of embolization materials and techniques to reduce recurrence and complications. Research into novel pharmacologic agents (e.g., new antifibrinolytics) is ongoing.
• Controversies:
  • Optimal timing of bronchoscopy in massive hemoptysis: Some argue for immediate bronchoscopy to localize and temporarily control, others for BAE as the first definitive intervention after stabilization, especially if CT has localized the source.
  • Role of surgery vs. repeat BAE for recurrent bleeding: Decision often depends on patient factors, resectability, and local expertise.
  • Role of TXA for massive hemoptysis: While safe, its efficacy in massive hemoptysis remains less clear compared to interventional procedures.

Key References

• Guidelines:
  • American Thoracic Society (ATS) and European Respiratory Society (ERS) clinical practice guidelines for specific lung diseases (e.g., bronchiectasis, TB).
  • British Thoracic Society (BTS) guidelines on hemoptysis (if available).
  • Interventional Radiology/Pulmonology society guidelines on bronchial artery embolization.
• Studies:
  • Landmark trials on the efficacy and safety of bronchial artery embolization.
  • Studies on the utility of nebulized tranexamic acid for hemoptysis.
  • Cohort studies on the causes and outcomes of hemoptysis.
• Reviews:
  • Comprehensive review articles on the diagnostic approach and management of hemoptysis in major medical journals (e.g., NEJM, Lancet, Chest, AJRCCM).
  • UpToDate and similar clinical reference databases.